Nothing Special   »   [go: up one dir, main page]

EA201000914A1 - Новые терапевтические подходы в лечении смт и связанных с ней расстройств - Google Patents

Новые терапевтические подходы в лечении смт и связанных с ней расстройств

Info

Publication number
EA201000914A1
EA201000914A1 EA201000914A EA201000914A EA201000914A1 EA 201000914 A1 EA201000914 A1 EA 201000914A1 EA 201000914 A EA201000914 A EA 201000914A EA 201000914 A EA201000914 A EA 201000914A EA 201000914 A1 EA201000914 A1 EA 201000914A1
Authority
EA
Eurasian Patent Office
Prior art keywords
related disorders
smt
treatment
new therapeutic
therapeutic approaches
Prior art date
Application number
EA201000914A
Other languages
English (en)
Other versions
EA019402B1 (ru
Inventor
Даниель Коэн
Илья Чумаков
Оксана Герасименко
Сергей Набирошкин
Original Assignee
Фарнекст
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фарнекст filed Critical Фарнекст
Publication of EA201000914A1 publication Critical patent/EA201000914A1/ru
Publication of EA019402B1 publication Critical patent/EA019402B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к композициям и способам для лечения болезни Шарко-Мари-Тусса и связанных с ней расстройств. Более конкретно, изобретение относится к комбинированной терапии для лечения указанного заболевания, воздействуя на экспрессию РМР22 у больного.
EA201000914A 2007-11-30 2008-11-28 Композиции и способ лечения болезни шарко-мари-тусса EA019402B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301614A EP2065038A1 (en) 2007-11-30 2007-11-30 New therapeutic approaches for treating Charcot-Marie-Tooth disease
US99180007P 2007-12-03 2007-12-03
PCT/EP2008/066468 WO2009068668A1 (en) 2007-11-30 2008-11-28 New therapeutic approaches for treating cmt and related disorders

Publications (2)

Publication Number Publication Date
EA201000914A1 true EA201000914A1 (ru) 2010-12-30
EA019402B1 EA019402B1 (ru) 2014-03-31

Family

ID=39264515

Family Applications (3)

Application Number Title Priority Date Filing Date
EA201791669A EA035711B1 (ru) 2007-11-30 2008-11-28 Применение d-сорбита для лечения смт и связанных с ним расстройств
EA201301078A EA032767B1 (ru) 2007-11-30 2008-11-28 Применение баклофена или его соли для лечения болезни шарко-мари-тусса (смт) и связанного с ней расстройства
EA201000914A EA019402B1 (ru) 2007-11-30 2008-11-28 Композиции и способ лечения болезни шарко-мари-тусса

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA201791669A EA035711B1 (ru) 2007-11-30 2008-11-28 Применение d-сорбита для лечения смт и связанных с ним расстройств
EA201301078A EA032767B1 (ru) 2007-11-30 2008-11-28 Применение баклофена или его соли для лечения болезни шарко-мари-тусса (смт) и связанного с ней расстройства

Country Status (24)

Country Link
US (6) US8992891B2 (ru)
EP (4) EP2065038A1 (ru)
JP (4) JP5953000B2 (ru)
KR (1) KR101546031B1 (ru)
CN (2) CN104257657B (ru)
AU (1) AU2008328745B2 (ru)
BR (1) BRPI0819678A2 (ru)
CA (3) CA3031484C (ru)
CY (2) CY1113980T1 (ru)
DK (2) DK2609916T3 (ru)
EA (3) EA035711B1 (ru)
ES (3) ES2408785T3 (ru)
HR (2) HRP20130345T1 (ru)
HU (1) HUE040596T2 (ru)
IL (1) IL205741A0 (ru)
LT (1) LT2609916T (ru)
MX (1) MX2010005709A (ru)
NZ (1) NZ585440A (ru)
PL (2) PL2211846T3 (ru)
PT (2) PT2211846E (ru)
SI (2) SI2609916T1 (ru)
TR (1) TR201819564T4 (ru)
WO (1) WO2009068668A1 (ru)
ZA (1) ZA201003610B (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US20110213193A1 (en) * 2008-08-28 2011-09-01 The Florida International University Board Of Trustees Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2502079B1 (en) * 2009-11-20 2015-01-28 Pharnext New diagnostic tools for charcot-marie-tooth disease
RU2583926C2 (ru) 2010-01-15 2016-05-10 ИНСЕРМ (Энститю Насьеналь де ла Санте э де ла Решерш Медикаль) Соединения для лечения аутизма
US20130227717A1 (en) * 2010-10-08 2013-08-29 Life Sciences Research Partners Vzw Hdac inhibitors to treat charcot-marie-tooth disease
CN102464610B (zh) * 2010-11-16 2014-07-30 北大方正集团有限公司 一种美替拉酮的制备方法
WO2012112933A1 (en) 2011-02-18 2012-08-23 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
JP2014511382A (ja) 2011-02-23 2014-05-15 コエルルウス リミテッド フルマゼニル錯体、それを含む組成物、およびその使用
UA113165C2 (xx) 2011-03-01 2016-12-26 Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
CN102247324B (zh) * 2011-07-14 2012-11-21 海南美兰史克制药有限公司 一种氟马西尼脂质体注射液
CN102887830B (zh) * 2012-09-04 2013-11-27 苏州弘森药业有限公司 一种盐酸酚苄明的制备方法
US10016142B2 (en) 2012-10-19 2018-07-10 Sidewaystrategies Llc Systems and methods for nerve mapping and monitoring
WO2014095757A1 (en) * 2012-12-17 2014-06-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
JP6300906B2 (ja) 2013-06-05 2018-03-28 ファーネクストＰｈａｒｎｅｘｔ 併用医薬有効成分（ａｐｉ）用安定性経口液剤
AU2015217796B2 (en) 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
UA118785C2 (uk) * 2014-02-24 2019-03-11 Фарнекст Композиції для лікування механічних пошкоджень нервів
WO2016187595A2 (en) * 2015-05-20 2016-11-24 Lupin Atlantis Holdings Sa Oral pharmaceutical composition of methylergonovine
US11136577B2 (en) 2016-03-09 2021-10-05 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
US11272871B2 (en) 2016-07-14 2022-03-15 Sidewaystrategies Llc System and methods for improving diagnostic evoked potential studies for functional assessments of nerves and nerve pathways
AU2017351638A1 (en) 2016-10-26 2019-06-13 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
JP7307059B2 (ja) 2017-07-28 2023-07-11 アプライド セラピューティクス， インコーポレイテッド ガラクトース血症を処置するための組成物および方法
EP3966320A4 (en) * 2019-05-07 2023-10-25 University of Miami TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS
IL297779A (en) * 2020-05-01 2022-12-01 Applied Therapeutics Inc Aldose reductase inhibitors for the treatment of sorbitol dehydrogenase deficiency
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen
US11523984B1 (en) * 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
WO2023182288A1 (ja) * 2022-03-22 2023-09-28 国立大学法人京都大学 シャルコー・マリー・ツース病の治療または予防薬

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US20030069213A1 (en) 1997-09-30 2003-04-10 Noritaka Ii Oral preparation
AU6058299A (en) * 1998-09-22 2000-04-10 Incyte Genomics, Inc. Human chaperone proteins
EP1117425A2 (en) 1998-10-02 2001-07-25 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
PL370793A1 (en) * 2001-07-04 2005-05-30 Sun Pharmaceutical Industries Limited Gastric retention controlled drug delivery system
CN1652752A (zh) * 2002-03-14 2005-08-10 欧罗赛铁克股份有限公司 盐酸纳曲酮组合物
AU2003220551A1 (en) * 2002-03-26 2003-10-13 Euro-Celtique S.A. Sustained-release gel coated compositions
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
JP2004049093A (ja) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd 腸内酪酸上昇食品組成物および医薬品
WO2004019938A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
US8992974B2 (en) * 2003-02-24 2015-03-31 Pharmaceuticals Productions, Inc. Transmucosal drug delivery system
CN104383542B (zh) * 2003-04-08 2017-09-26 普罗热尼奇制药公司 包含甲基纳曲酮的药物配方
AU2004229551A1 (en) * 2003-04-14 2004-10-28 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
WO2005032555A2 (en) * 2003-09-25 2005-04-14 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
WO2005053612A2 (en) 2003-11-26 2005-06-16 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
WO2007134136A2 (en) * 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007249435A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 HT receptor mediated neurogenesis
ES2365574T3 (es) 2007-01-11 2011-10-07 Xenoport, Inc. Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento.
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
US7806721B2 (en) * 2007-08-02 2010-10-05 Tyco Electronics Corporation Patch panel modular jack assembly
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en) * 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
WO2012117076A2 (en) 2011-03-01 2012-09-07 Pharnext Baclofen and acamprosate based therapy of neurogical disorders
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
JP6300906B2 (ja) 2013-06-05 2018-03-28 ファーネクストＰｈａｒｎｅｘｔ 併用医薬有効成分（ａｐｉ）用安定性経口液剤
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
CA3031484A1 (en) 2009-06-04
KR20100088160A (ko) 2010-08-06
PT2609916T (pt) 2019-01-10
HRP20182147T1 (hr) 2019-03-08
HRP20182147T8 (hr) 2019-04-19
CA3031490C (en) 2021-05-04
HRP20130345T1 (hr) 2013-07-31
MX2010005709A (es) 2010-11-05
EA032767B1 (ru) 2019-07-31
CY1113980T1 (el) 2016-07-27
US20180360785A1 (en) 2018-12-20
PL2609916T3 (pl) 2019-03-29
EP2609916B1 (en) 2018-11-07
CN101883561B (zh) 2014-07-30
EP3459535A1 (en) 2019-03-27
US10441558B2 (en) 2019-10-15
WO2009068668A1 (en) 2009-06-04
CA3031490A1 (en) 2009-06-04
JP2011504915A (ja) 2011-02-17
ES2703508T3 (es) 2019-03-11
US10463640B2 (en) 2019-11-05
EP2211846B1 (en) 2013-02-27
EP3459535B1 (en) 2020-08-12
EA201791669A2 (ru) 2017-12-29
EA035711B1 (ru) 2020-07-29
EA019402B1 (ru) 2014-03-31
US20200155491A1 (en) 2020-05-21
CN104257657A (zh) 2015-01-07
ZA201003610B (en) 2011-06-29
CA2705408C (en) 2019-04-23
NZ585440A (en) 2011-12-22
JP6608309B2 (ja) 2019-11-20
US20180250289A1 (en) 2018-09-06
LT2609916T (lt) 2019-02-11
KR101546031B1 (ko) 2015-08-25
DK2609916T3 (en) 2019-01-21
SI2211846T1 (sl) 2013-07-31
ES2408785T3 (es) 2013-06-21
AU2008328745A1 (en) 2009-06-04
EP2065038A1 (en) 2009-06-03
TR201819564T4 (tr) 2019-01-21
DK2211846T3 (da) 2013-04-29
PL2211846T3 (pl) 2013-09-30
SI2609916T1 (sl) 2019-03-29
IL205741A0 (en) 2010-11-30
CA2705408A1 (en) 2009-06-04
HUE040596T2 (hu) 2019-03-28
US20150157626A1 (en) 2015-06-11
US20100310641A1 (en) 2010-12-09
US20180338969A1 (en) 2018-11-29
JP2016145227A (ja) 2016-08-12
EA201791669A3 (ru) 2018-03-30
CA3031484C (en) 2021-05-04
CN104257657B (zh) 2017-07-04
JP2018109043A (ja) 2018-07-12
CY1121183T1 (el) 2020-05-29
US10322101B2 (en) 2019-06-18
PT2211846E (pt) 2013-05-10
US8992891B2 (en) 2015-03-31
JP5953000B2 (ja) 2016-07-13
EP2211846A1 (en) 2010-08-04
JP2019142917A (ja) 2019-08-29
CN101883561A (zh) 2010-11-10
EA201301078A1 (ru) 2014-06-30
AU2008328745B2 (en) 2014-01-30
BRPI0819678A2 (pt) 2017-05-09
ES2831855T3 (es) 2021-06-09
EP2609916A1 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
CY1121134T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συγκολλησης
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
CY1120807T1 (el) Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
EA200900177A1 (ru) Замещенные ациланилиды и способы их применения
EA201370208A1 (ru) Формы рифаксимина и их применение
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
CY1116344T1 (el) Κυτταρα προερχομενα απο ιστο ομφαλιου λωρου για την θεραπεια νευροπαθητικου πονου και σπαστικοτητας
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EA201071038A1 (ru) Производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
EA201300558A1 (ru) Соединения и способы для купирования боли
EA200901211A1 (ru) Антигены белка с5 и их применение
NO20092637L (no) Fremgangsmater for behandling
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
MX337575B (es) Compuestos de sulfona y métodos para lafabricación y uso de éstos.
ME02414B (me) Tretman kronove bolesti lakvinimodom
EA200970224A1 (ru) Лечение заболеваний хряща
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM